The present invention relates to Human Immunodeficiency Virus (HIV) treatment. In particular, the invention relates to a pharmaceutical composition comprising cabotegravir or a pharmaceutically acceptable salt thereof, polyethylene glycol and poloxamer useful as a long acting HIV treatment.

A composition containing amitochodrially-targeted antioxidant of the SkQ type and a polyacrylate, agarose, agar-agar orhyaluronic acid polymer useful for production of pharmaceutical, medicinal and cosmetic compositions having good stability. Such compositions may usefully also include lactic acid.

A composition containing amitochodrially-targeted antioxidant of the SkQ type and a polyacrylate, agarose, agar-agar orhyaluronic acid polymer useful for production of pharmaceutical, medicinal and cosmetic compositions having good stability. Such compositions may usefully also include lactic acid.

An anti-aggregation agent of the present invention contains, as an anti-aggregation ingredient, at least one selected from the group consisting of polyoxyethylene cetyl ether, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene polyoxypropylene glycols having an average molecular weight of 3000 to 13000 and combinations thereof. According to the present invention, in a container whose inner wall is treated with silicone oil, aggregation of a poorly water-soluble drug caused by the silicone oil can be prevented.

An anti-aggregation agent of the present invention contains, as an anti-aggregation ingredient, at least one selected from the group consisting of polyoxyethylene cetyl ether, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene polyoxypropylene glycols having an average molecular weight of 3000 to 13000 and combinations thereof. According to the present invention, in a container whose inner wall is treated with silicone oil, aggregation of a poorly water-soluble drug caused by the silicone oil can be prevented.

The present disclosure is directed to formulations and methods for treating or preventing head pain, including migraines, with dihydroergotamine mesylate.

The present disclosure is directed to formulations and methods for treating or preventing head pain, including migraines, with dihydroergotamine mesylate.

Disclosed are niclosamide formulations for use as antiviral therapy. The formulations disclosed herein may be used for treating a sexually-transmitted virus or a respiratory virus (e.g., coronavirus).

Disclosed are niclosamide formulations for use as antiviral therapy. The formulations disclosed herein may be used for treating a sexually-transmitted virus or a respiratory virus (e.g., coronavirus).

This invention provides compositions for controlled localized depositing of one or more drugs within a subject. More particularly, described herein are compositions comprising a) a polyethylene glycol (PEG) composition having a first low molecular weight PEG (Mw between 200-500 Da) and a second low molecular weight PEG (Mw between 500-2000 Da) and b) a mucoadhesive in polymer. Alternatively, composition may comprise a) a polyethylene glycol (PEG) composition having a first low molecular weight PEG (Mw between 200-500 Da) and a second low molecular weight PEG (Mw between 500-2000 Da), b) a water insoluble polymer and c) a mucoadhesive polymer. Furthermore, the composition may further comprise one or more drugs. Also provided are methods of manufacturing and administering the compositions described herein, which are used as biodegradable, injectable mucoadhesive low-viscosity pastes.